HiFiBiO Therapeutics

HiFiBiO Therapeutics, founded in 2017 and based in Cambridge, USA, is a private biotechnology company advancing a pipeline of immunotherapies in immuno-oncology and inflammatory/immunological diseases. Its core asset is the DIS® platform, a data-driven engine combining high-resolution single-cell analysis with computational biology to deconvolute disease biology and accelerate therapeutic development. The company has demonstrated strong translational capabilities, with multiple INDs cleared and programs in Phase 1 trials, supported by a broad network of over 12 strategic partnerships.

Drug Intelligence Science (DIS®) platform integrating proprietary single-cell technology with AI/ML analytics for target discovery, antibody selection, and biomarker identification.

HiFiBiO competes in the crowded immuno-oncology and immunology spaces against large pharmaceutical companies and numerous biotechs. Its differentiation lies in its integrated DIS® platform, which uses single-cell and AI to derive targets and drugs directly from patient samples, a approach also being pursued by other data-centric biotechs like Adaptive Biotechnologies and Century Therapeutics.